Neoadjuvant Chemotherapy–Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study

Abstract

After stratifying MIBC patients by NAC efficacy, definite responders achieved a satisfactory bladder-sparing rate, prognosis, and bladder function. The CR rate reflected the real NAC efficacy for MIBC. This therapy is worth verifying through multicenter research.

References

Page 1

	Year	Citations
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer H. Barton Grossman, Ronald B. Natale, Catherine M. Tangen, New England Journal of Medicine	2003	2.6K
International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial Journal of Clinical Oncology	2011	933
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial Dipen J. Parekh, Isildinha M. Reis, Erik P. Castle, The Lancet UrologySurgical OncologyMedicineMinimally Invasive ProcedureOutcomes Research	2018	737
Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. William U. Shipley, Kathryn Winter, Donald S. Kaufman, Journal of Clinical Oncology	1998	484
Long-Term Outcomes of Selective Bladder Preservation by Combined-Modality Therapy for Invasive Bladder Cancer: The MGH Experience Jason A. Efstathiou, Daphna Y. Spiegel, William U. Shipley, European Urology UrologySelective Bladder PreservationSurgical OncologyGenitourinary CancerMedicine	2011	422
Radical Cystectomy for Urothelial Carcinoma of the Bladder Without Neoadjuvant or Adjuvant Therapy: Long-Term Results in 1100 Patients Richard E. Hautmann, Robert C. de Petriconi, Christina Pfeiffer, European Urology Radical CystectomyUrologySurgical OncologyUrologic Cancer EpidemiologyGenitourinary Cancer	2012	409
Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience Nicholas J. Giacalone, William U. Shipley, R.H. Clayman, European Urology Urological ResearchUrologySurgical OncologyVoiding DysfunctionGenitourinary Cancer	2017	390
Urinary Bladder Cancer: Diffusion-weighted MR Imaging—Accuracy for Diagnosing T Stage and Estimating Histologic Grade Mitsuru Takeuchi, Shigeru Sasaki, Masato Ito, Radiology	2009	356
Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic Girish S. Kulkarni, Thomas Hermanns, Yanliang Wei, Journal of Clinical Oncology Tmt GroupUrologySurgical OncologyUrologic Cancer EpidemiologyRadical Cystectomy	2017	295
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer Matthew D. Galsky, Sumanta K. Pal, Simon Chowdhury, Cancer	2015	194

Page 1